Ignite Creation Date:
2025-12-24 @ 4:11 PM
Ignite Modification Date:
2026-03-01 @ 8:56 PM
Study NCT ID:
NCT04539366
Status:
SUSPENDED
Last Update Posted:
2025-11-03
First Post:
2020-09-04
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial
Sponsor:
National Cancer Institute (NCI)
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Recurrent Childhood Neuroblastoma | View |
| None | Recurrent Childhood Osteosarcoma | View |
| None | Recurrent Neuroblastoma | View |
| None | Recurrent Osteosarcoma | View |
| None | Refractory Childhood Neuroblastoma | View |
| None | Refractory Childhood Osteosarcoma | View |
| None | Refractory Neuroblastoma | View |
| None | Refractory Osteosarcoma | View |
Keywords: